177 related articles for article (PubMed ID: 33285521)
1. Impact of Exercise on Chemotherapy Tolerance and Survival in Early-Stage Breast Cancer: A Nonrandomized Controlled Trial.
Kirkham AA; Gelmon KA; Van Patten CL; Bland KA; Wollmann H; McKenzie DC; Landry T; Campbell KL
J Natl Compr Canc Netw; 2020 Dec; 18(12):1670-1677. PubMed ID: 33285521
[TBL] [Abstract][Full Text] [Related]
2. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
Foukakis T; von Minckwitz G; Bengtsson NO; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellström M; Johansson H; Anderson H; Malmström P; Gnant M; Greil R; Möbus V; Bergh J;
JAMA; 2016 Nov; 316(18):1888-1896. PubMed ID: 27825007
[TBL] [Abstract][Full Text] [Related]
3. Effects of exercise during adjuvant chemotherapy on breast cancer outcomes.
Courneya KS; Segal RJ; McKenzie DC; Dong H; Gelmon K; Friedenreich CM; Yasui Y; Reid RD; Crawford JJ; Mackey JR
Med Sci Sports Exerc; 2014 Sep; 46(9):1744-51. PubMed ID: 24633595
[TBL] [Abstract][Full Text] [Related]
4. Multi-agent chemotherapy for early breast cancer.
Early Breast Cancer Trialists' Collaborative Group
Cochrane Database Syst Rev; 2002; (1):CD000487. PubMed ID: 11869577
[TBL] [Abstract][Full Text] [Related]
5. Dexrazoxane added to doxorubicin-based adjuvant chemotherapy of breast cancer: a retrospective cohort study with a comparative analysis of toxicity and survival.
Tahover E; Segal A; Isacson R; Rosengarten O; Grenader T; Gips M; Cherny N; Heching NI; Mesika L; Catane R; Gabizon A
Anticancer Drugs; 2017 Aug; 28(7):787-794. PubMed ID: 28562379
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group.
Martin M; Villar A; Sole-Calvo A; Gonzalez R; Massuti B; Lizon J; Camps C; Carrato A; Casado A; Candel MT; Albanell J; Aranda J; Munarriz B; Campbell J; Diaz-Rubio E;
Ann Oncol; 2003 Jun; 14(6):833-42. PubMed ID: 12796019
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.
Mackey JR; Pieńkowski T; Crown J; Sadeghi S; Martin M; Chan A; Saleh M; Sehdev S; Provencher L; Semiglazov V; Press MF; Sauter G; Lindsay M; Houé V; Buyse M; Drevot P; Hitier S; Bensfia S; Eiermann W
Ann Oncol; 2016 Jun; 27(6):1041-1047. PubMed ID: 26940688
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of Tibetan yoga in patients with breast cancer undergoing chemotherapy.
Chaoul A; Milbury K; Spelman A; Basen-Engquist K; Hall MH; Wei Q; Shih YT; Arun B; Valero V; Perkins GH; Babiera GV; Wangyal T; Engle R; Harrison CA; Li Y; Cohen L
Cancer; 2018 Jan; 124(1):36-45. PubMed ID: 28940301
[TBL] [Abstract][Full Text] [Related]
10. Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.
Martín M; Ruiz Simón A; Ruiz Borrego M; Ribelles N; Rodríguez-Lescure Á; Muñoz-Mateu M; González S; Margelí Vila M; Barnadas A; Ramos M; Del Barco Berron S; Jara C; Calvo L; Martínez-Jáñez N; Mendiola Fernández C; Rodríguez CA; Martínez de Dueñas E; Andrés R; Plazaola A; de la Haba-Rodríguez J; López-Vega JM; Adrover E; Ballesteros AI; Santaballa A; Sánchez-Rovira P; Baena-Cañada JM; Casas M; del Carmen Cámara M; Carrasco EM; Lluch A
J Clin Oncol; 2015 Nov; 33(32):3788-95. PubMed ID: 26416999
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study.
Jones SE; Collea R; Paul D; Sedlacek S; Favret AM; Gore I; Lindquist DL; Holmes FA; Allison MAK; Brooks BD; Portillo RM; Vukelja SJ; Steinberg MS; Stokoe C; Crockett MW; Wang Y; Asmar L; Robert NJ; O'Shaughnessy J
Lancet Oncol; 2013 Oct; 14(11):1121-1128. PubMed ID: 24007746
[TBL] [Abstract][Full Text] [Related]
12. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
Martín M; Ruiz A; Ruiz Borrego M; Barnadas A; González S; Calvo L; Margelí Vila M; Antón A; Rodríguez-Lescure A; Seguí-Palmer MA; Muñoz-Mateu M; Dorca Ribugent J; López-Vega JM; Jara C; Espinosa E; Mendiola Fernández C; Andrés R; Ribelles N; Plazaola A; Sánchez-Rovira P; Salvador Bofill J; Crespo C; Carabantes FJ; Servitja S; Chacón JI; Rodríguez CA; Hernando B; Álvarez I; Carrasco E; Lluch A
J Clin Oncol; 2013 Jul; 31(20):2593-9. PubMed ID: 23733779
[TBL] [Abstract][Full Text] [Related]
13. Impact of Cumulative Chemotherapy Dose on Survival With Adjuvant FEC-D Chemotherapy for Breast Cancer.
Veitch Z; Khan OF; Tilley D; Tang PA; Ribnikar D; Stewart DA; Kostaras X; King K; Lupichuk S
J Natl Compr Canc Netw; 2019 Aug; 17(8):957-967. PubMed ID: 31390594
[TBL] [Abstract][Full Text] [Related]
14. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
[TBL] [Abstract][Full Text] [Related]
15. Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).
Mavroudis D; Matikas A; Malamos N; Papakotoulas P; Kakolyris S; Boukovinas I; Athanasiadis A; Kentepozidis N; Ziras N; Katsaounis P; Saloustros E; Georgoulias V;
Ann Oncol; 2016 Oct; 27(10):1873-8. PubMed ID: 27502729
[TBL] [Abstract][Full Text] [Related]
16. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet; 1998 Sep; 352(9132):930-42. PubMed ID: 9752815
[TBL] [Abstract][Full Text] [Related]
17. Premature ovarian failure and body composition changes with adjuvant chemotherapy for breast cancer.
Gordon AM; Hurwitz S; Shapiro CL; LeBoff MS
Menopause; 2011 Nov; 18(11):1244-8. PubMed ID: 21814159
[TBL] [Abstract][Full Text] [Related]
18. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
[TBL] [Abstract][Full Text] [Related]
19. Risk of emergency hospitalisation and survival outcomes following adjuvant chemotherapy for early breast cancer in New South Wales, Australia.
Tervonen HE; Chen TYT; Lin E; Boyle FM; Moylan EJ; Della-Fiorentina SA; Beith J; Johnston A; Currow DC
Eur J Cancer Care (Engl); 2019 Sep; 28(5):e13125. PubMed ID: 31222826
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
